TrialBlood advances2024

Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial.

Amitkumar Mehta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.